Takeda To Buy IDM Pharma Of U.S., Maker Of Bone Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical said it intends to buy U.S. drug maker IDM Pharma for $66.7 million in cash. With the purchase, Takeda expects to get the American firm's Mepact (mifamurtide), a cancer drug for treating osteosarcoma. The drug has yet to be approved by the U.S. FDA, but it recently was cleared for marketing in Europe. Takeda's European CEO said the drug is capable of contributing in the near term to the firm's "top-line growth." (Click here for more